Idactamab INT-001 represents the interesting therapeutic approach for treating specific hematologic malignancies. The antibody demonstrates the distinct process of function, particularly binding to CD-38, the https://mediajx.com/story27754013/idacta-mab-int-001-a-novel-immunoglobulin-during-progression